CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 180 enrolled
Drug / intervention
Silicone tubedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00706251
NCT00706251N/ACompleted

Long Term Follow up of Nasolacrimal Intubation in Adults With Mild Epiphora

Shaare Zedek Medical Center·observational·Posted Jun 27, 2008·Updated Jun 27, 2008

In Brief

An observational study evaluating Silicone tube for Lacrimal Apparatus Diseases and Dacryocystitis. Completed, enrolled 180 participants across 1 site.

Detailed Summary

For patients with chronic epiphora, Dacryocystorhinostomy is currently the gold standard treatment, with a success rate of 80-90% according to literature. Another available treatment, which is far less used, in nasolacrimal intubation, using a silicone tube. In our study, we would like to find the efficacy of nasolacrimal duct intubation, which was performed in our medical center on a few hundred patients with mild epiphora. Study hypothesis: nasolacrimal intubation in adults, with a clinically mild epiphora, is close in it's efficacy to the Dacryocystorhinostomy procedure.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesIsrael
Collaborators--

Timeline

N/ACompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 27, 2008
Enrollment StartJan 1, 2000
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 18.0 years ago

Interventions

Silicone tubedevice

Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.